-
Patent Agency Ranking
公开(公告)号：US20160272710A1
公开(公告)日：2016-09-22
申请号：US15090002
申请日：2016-04-04
Applicant: Novo Nordisk A/S
Inventor： Ida Hilden , Lars Christian Petersen , Jens Breinholt , Mette Dahl Andersen , Jais Rose Bjelke , Thomas Egebjerg
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K38/00 , C07K14/745 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/64 , C07K2317/92 , C07K2319/33
Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
Abstract translation: 本发明涉及促凝血融合蛋白，编码所述融合蛋白的多核苷酸和表达所述融合蛋白的细胞。 此外，本发明涉及用作药物的融合蛋白。 具有凝血病的个体，例如具有或不具有抑制剂的血友病A和B，可以用本发明的融合蛋白进行治疗。
-
公开(公告)号：US10106606B2
公开(公告)日：2018-10-23
申请号：US15090002
申请日：2016-04-04
Applicant: Novo Nordisk A/S
Inventor： Ida Hilden , Lars Christian Petersen , Jens Breinholt , Mette Dahl Andersen , Jais Rose Bjelke , Thomas Egebjerg , Jes Thorn Clausen , Susanne Nedergaard Grell
IPC: C07K16/28 , C07K14/745 , A61K38/00
Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
-
3.发明授权Antibodies that are capable of specifically binding tissue factor pathway inhibitor 有权能够特异性结合组织因子途径抑制剂的抗体公开(公告)号：US09228022B2
公开(公告)日：2016-01-05
申请号：US13780631
申请日：2013-02-28
Applicant: Novo Nordisk A/S
Inventor： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen , Anders Svensson
CPC classification number: C07K16/38 , C07K2317/34 , C07K2317/76
Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Abstract translation: 本发明涉及能够特异性结合组织因子途径抑制剂（TFPI），中和游离TFPI并降低血液凝血时间的抗体。 此外，本发明涉及编码这种抗体的多核苷酸以及包含多核苷酸或表达本发明的抗体的细胞。 这样的抗体可用于治疗具有凝血病的受试者，单独和与第二药剂组合。
-
4.发明申请Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor 审中-公开能够特异性结合组织因子途径抑制剂的抗体公开(公告)号：US20130253173A1
公开(公告)日：2013-09-26
申请号：US13780631
申请日：2013-02-28
Applicant: NOVO NORDISK A/S
Inventor： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen , Anders Svensson
IPC: C07K16/38
CPC classification number: C07K16/38 , C07K2317/34 , C07K2317/76
Abstract: The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Abstract translation: 本发明涉及能够特异性结合组织因子途径抑制剂（TFPI），中和游离TFPI并降低血液凝血时间的抗体。 此外，本发明涉及编码这种抗体的多核苷酸以及包含多核苷酸或表达本发明的抗体的细胞。 这样的抗体可用于治疗具有凝血病的受试者，单独和与第二药剂组合。
-
公开(公告)号：US20190062429A1
公开(公告)日：2019-02-28
申请号：US16130339
申请日：2018-09-13
Applicant: Novo Nordisk A/S
Inventor： Ida Hilden , Lars Christian Petersen , Jens Breinholt , Mette Dahl Andersen , Jais Rose Bjelke , Thomas Egebjerg , Jes Thorn Clausen , Susanne Nedergaard Grell
IPC: C07K16/28 , C07K14/745
Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
-
-
-
-
Search Results
5
records
(took 0.018 seconds)
